Impact of Combining Immune Checkpoint Inhibitors with Chemotherapy in the Management of Advanced Serous Endometrial Adenocarcinoma

Chemo-immunotherapy is a relatively recent approach to the treatment of advanced or relapsed endometrial cancer. The aim of these therapies is to remove immune suppression, enabling the immune system to better recognise and destroy cancer cells. We report a clinical case of stage 4 endometrial cancer in a 69-year-old patient with several commorbidities in whom we obtained a complete response after four cycles of paclitaxel+carboplatin combined with pembrolizumab followed by maintenance immunotherapy. Immunotherapy combined with chemotherapy is a relatively recent approach to the treatment of advanced or relapsed endometrial cancer. This case report demonstrates the importance of adding immunotherapy to chemotherapy in the management of advanced endometrial cancer.